


BIOPHARMACEUTICALS



Advantages of HALO® OLIGO C18

378



PEAK IDENTITIES

- 1. 10 mer
- 2. 15 mer
- 3. 20 mer
- 4. 25 mer
- 5. 30 mer
- 6. 40 mer
- 7. 50 mer
- 8. 60 mer
- * Tris HCI/EDTA

TEST CONDITIONS:

Column: HALO 120 Å OLIGO C18, 2.7 μ m, 2.1 x 50 mm Competitor: Oligo 130 Å C18, 1.7 μ m, 2.1 x 50 mm Mobile Phase A: 100mM TEAA, Adjusted to pH = 8.5

Mobile Phase B: ACN

Gradient: Time %B 0.0 5 10.0 11 11.0 11 11.5 0 16.5 0

Flow Rate: 0.5 mL/min

Back Pressure: HALO® - 140 bar

Competitor - 255 bar

Temperature: 60 °C

Injection: 1.0 µL, 10µg on Column

Sample Solvent: 10mM Tris HCl/1mM EDTA pH=8.0

Wavelength: PDA, 254 nm

Flow Cell: 1 µL Data Rate: 100 Hz Response Time: 0.025 sec LC System: Shimadzu Nexera X2 An oligonucleotide ladder of mixed sequence and length is separated on the HALO® OLIGO C18 column and a competitor oligonucleotide column under high pH conditions. The OLIGO column performs well in comparison to the competitor. The oligomers of 20 base length or higher begin to tail heavily on the competitor column. The same oligomers show no tailing on the HALO® column which shows the utility of the OLIGO C18 column. While the tailing of the competitor column may be misrepresented by poor loading, both the HALO® and competitor columns were QC tested to ensure a fair comparison. Both columns passed QC which verified each column.



